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Abstract
 
The production of interleukin (IL)-12 is critical for the development of interferon (IFN)-
 
 
 
–
dependent resistance to 
 
Toxoplasma gondii
 
. Nevertheless, when this response is dysregulated,
such as occurs in the absence of IL-10, the uncontrolled inflammation that results can have le-
thal consequences for the host. Recently, we demonstrated that lipoxin (LX)A
 
4
 
, an eicosanoid
mediator that depends on 5-lipoxygenase (LO) for its biosynthesis, exerts a regulatory role on
dendritic cell IL-12 production triggered artificially by a 
 
T. gondii
 
 extract. We now formally es-
tablish the physiological relevance of this pathway in the systemic control of IL-12 production
 
induced by live 
 
T. gondii
 
 infection and demonstrate its function to be distinct from that of IL-10.
Thus, 
 
T. gondii
 
–exposed wild-type, but not 5-LO–deficient animals, produced high levels of
serum LXA
 
4 
 
beginning at the onset of chronic infection. Moreover, 5-LO
 
 
 
/
 
 
 
, in contrast to
wild-type mice, succumbed during the same period displaying a marked encephalitis. The in-
creased mortality of the 5-LO
 
 
 
/
 
  
 
animals was also associated with significant elevations of IL-12
and IFN-
 
  
 
and was completely prevented by the administration of a stable LXA
 
4 
 
analogue. To-
gether, these findings demonstrate a new pathway involving the induction of host LXs for the
in vivo regulation of proinflammatory responses during microbial infection.
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Introduction
 
Cell-mediated immune responses to infectious agents must
be carefully regulated to avoid damage to host tissues. Cy-
tokines, such as IL-12, IFN-
 
 
 
, and TNF, which are criti-
cal for host resistance to many intracellular pathogens, are
also detrimental when expressed in an uncontrolled manner
(1). Murine infection with the protozoan parasite 
 
Toxo-
plasma gondii
 
 provides an excellent example of this con-
cept. IL-12–dependent production of IFN-
 
  
 
is essential
for the control of both acute and chronic 
 
T. gondii 
 
infec-
tion (2). At the same time, IL-10–deficient mice, which
display normal resistance to infection, succumb to excessive
tissue damage associated with the overproduction of the
proinflammatory cytokines listed above (3, 4). Similar sce-
 
narios in which dysregulated pathogen-induced cytokine
production results in inflammatory disease have been ob-
served in a wide variety of parasitic (5) and bacterial (6,
7) infections.
In addition to down-regulatory cytokines, other endog-
enous mediators may play an important role in controlling
excess production of host-protective proinflammatory cy-
tokines. In the process of studying the response of murine
dendritic cells (DCs)
 
*
 
 to 
 
T. gondii
 
, we recently uncovered a
novel mechanism for the regulation of IL-12 production
involving lipoxin (LX)A
 
4
 
, an eicosanoid product generated
from arachidonic acid. Splenic DCs from mice injected
with soluble tachyzoite antigen (STAg) of 
 
T. gondii
 
 pro-
duce high levels of IL-12 by a mechanism dependent on
the cell-surface expression of the chemokine receptor
CCR5 (8). However, this response is short-lived and cannot
be restimulated with STAg for a period of 
 
 
 
1 wk (9). We
found that the observed loss of responsiveness was asso-
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ciated with reduced expression of CCR5 by DCs, a
phenomenon dependent on the presence of an enzyme,
5-lypoxygenase (5-LO), critical in the generation of LXA
 
4
 
.
Moreover, suppressed IL-12 production by DCs could be
induced exogenously by the administration of a stable
LXA
 
4 
 
mimetic (10). Other eicosanoids generated by the
5-LO pathway including leukotrienes (LTB
 
4
 
, LTC
 
4
 
, and
LTD
 
4
 
) as well as 5-Oxo-ETE, 5-HETE, and a battery of
related compounds were not able to mimic the activity of
LXA
 
4 
 
when tested in the nanogram to microgram range.
On the basis of the evidence above, we hypothesized that
the induction of LXA
 
4 
 
by STAg is the mechanism responsi-
ble for the down-regulation of CCR5-dependent IL-12
production observed after the administration of this micro-
bial stimulus.
Although LXA
 
4 
 
is able to potently suppress 
 
T. gondii
 
–
induced IL-12 production by DCs, our previous demon-
stration of this phenomenon involved a nonphysiological
model system using STAg injection. A critical question re-
mained as to whether the same mechanism functions in
the regulation of IL-12 and IL-12–dependent IFN-
 
  
 
syn-
thesis during natural infection with 
 
T. gondii
 
 and whether
it impacts on the outcome of disease. In this study, we
have addressed this issue by investigating the induction of
LXA
 
4 
 
after the infection of mice with an avirulent strain of
the parasite and after the fate of such infections in 5-LO
 
 
 
/
 
 
 
animals incapable of generating the eicosanoid. Our find-
ings reveal a critical role for 
 
T. gondii
 
–induced LXA
 
4
 
, dis-
tinct from that of IL-10 in the regulation of IL-12–depen-
dent IFN-
 
  
 
production and tissue damage during infection
with this protozoan. Thus, they demonstrate a previously
unrecognized function for this lipid mediator in modulat-
ing the inflammatory response triggered in vivo by infec-
tious agents.
 
Materials and Methods
 
Animals.
 
Wild-type controls (B6, 129S F2/J) and 5-LO–
deficient (B6, 129S Alox-5) mice were obtained from The Jack-
son Laboratory and bred and maintained in an NIAID Associa-
tion for the Assessment and Accreditation of Laboratory Animal
Care–accredited animal facility. Previous studies with the experi-
mental model used indicated no major differences in the suscepti-
bility to 
 
T. gondii
 
 of B6 and B6 
 
  
 
129 crosses over the first 3 mo
of infection (11). Animals 5–7-wk-old of both sexes were used
on a randomized basis in all experiments.
 
Infections and In Vivo Treatments. T. gondii
 
 cysts (ME49 strain)
were recovered from brain homogenates from chronically in-
fected mice and suspended in PBS. Animals were experimentally
infected by intraperitoneal injection with 20 cysts per mouse. In
some experiments, animals also received five intraperitoneal in-
jections in alternating days with vehicle (0.2 ml/animal), IL-10
(0.1 
 
 
 
g/animal), and 15-epi-16-phenoxy-parafluoro-LXA
 
4
 
-methyl
ester (1 
 
 
 
g/animal/treatment, 0.025 mg/kg; Berlex Biosciences)
from days 10–20 after infection. The LX analogue was prepared
by total organic synthesis and isolated and characterized as previ-
ously described (12).
 
LXA
 
4
 
, Nitrite (NO
 
2
 
), and Cytokine Determinations.
 
Serum levels
of LXA
 
4 
 
were measured according to the procedure of Levy et al.
 
(13) using a commercial kit (Neogen). NO
 
2 
 
levels were evaluated
in culture supernatants by means of the Griess reaction (3). IL-
12p40, IFN-
 
 
 
, and IL-10 serum levels were measured by ELISA
as previously described (8, 14), whereas macrophage inflamma-
tory protein (MIP)-1
 
 
 
, MIP-1
 
 
 
, and RANTES were quantitated
using commercial ELISA kits (R&D Systems).
 
In Situ Staining and Flow Cytometry.
 
In situ immunostaining
of CD4, CD8, CD11c, IL-12p40, and CCR5 was performed as
previously described (8). In brief, acetone-fixed serial sections
were incubated with biotin-conjugated antibodies against CD4,
CD8, CD11c, or CCR5 (Becton Dickinson). After washing, sec-
tions were exposed to streptavidin-conjugated horseradish perox-
idase (Jackson ImmunoResearch Laboratories) and the reaction
was developed using a metal-conjugated horseradish peroxidase
substrate (Pierce Chemical Co.). In some experiments, sections
were simultaneously double stained with rat anti–IL-12p40 mAb
and the reaction was developed with anti–rat IgG AlexaFluor 594
(Molecular Probes) followed by counterstaining with DAPI (Mo-
lecular Probes). After additional washing, the sections were ex-
amined microscopically and the images were recorded with a
digital camera (
 
 
 
200). For flow cytometric analysis, brain mono-
nuclear cell suspensions were prepared and stained with anti-
CD11c, anti-CD11b, and anti-CCR5 (Becton Dickinson) as
previously described (15).
 
Macrophage Cultures.
 
Thioglycollate-elicited macrophages were
obtained from C57Bl/6 mice 5 d after injection. Cells were
plated, incubated with different concentrations of LXA
 
4
 
, IL-10,
or vehicle for 1 h, and infected with 
 
T. gondii
 
 tachyzoites (5:1
parasite/macrophage ratio). After 4 or 48 h the cultures were
stopped, the cells were fixed, Wright-Giemsa stained, and the
number of intracellular parasites were evaluated microscopically.
In parallel cultures, 24-h supernatants were collected for later
evaluation of NO
 
2
 
, cytokine, and chemokine levels.
 
Statistical Analysis.
 
The statistical significance of differences in
mean values between experimental versus control or vehicle
treated samples was evaluated by means of Student’s 
 
t 
 
test. Differ-
ences were considered to be significant at P values of 
 
 
 
 0.05.
 
Results
 
T. gondii Infection Induces LXA
 
4 
 
Production In Vivo.
 
To
address whether the regulatory effects of LXA
 
4 
 
on IL-12
production play a role in the outcome of in vivo infection
with 
 
T. gondii
 
, we first determined whether the mediator is
induced after natural exposure to the live parasite. As
shown in Fig. 1 A, LXA
 
4 
 
was detected at substantial levels
in sera of wild-type mice after intraperitoneal inoculation
with 
 
T. gondii
 
 cysts beginning at 10 d and reaching a pla-
teau 15 d after infection. Importantly, only baseline levels
of the eicosanoid were detected in simultaneously infected
5-LO
 
 
 
/
 
  
 
mice, confirming the dependence of LXA
 
4 
 
pro-
duction on 5-LO in vivo. In contrast, serum IL-10 levels
peaked earlier (5–10 d after infection) and were only mar-
ginally affected by 5-LO deficiency (Fig. 1 B). These ob-
servations demonstrate that IL-10 and LXA
 
4 
 
are induced
with different kinetics, suggesting that they may involve
distinct pathways.
 
5-LO
 
 
 
/
 
  
 
Mice Display Increased Susceptibility to T. gondii
Infection.
 
To assess whether the induction of LXA
 
4 
 
plays a
role in host resistance, we compared the outcome of infec-
tion in wild-type and 5-LO
 
 
 
/
 
  
 
mice. As shown in Fig. 2, A 
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and B, ME49-inoculated 5-LO–deficient mice exhibited
an accelerated loss in body weight and abruptly succumbed
between 27 and 31 d after infection in contrast to the long-
term survival of wild-type animals. Importantly, this in-
creased susceptibility to 
 
T. gondii
 
 was not the result of de-
fective immune control of the parasite. Thus, infected
5-LO
 
 
 
/
 
  
 
mice consistently showed a lower rather than
higher burden of 
 
T. gondii
 
 tissue cysts in the brain than the
wild-type controls (Fig. 2 C). This finding suggested that
parasite-induced immune responses are enhanced in the
absence of LXA
 
4 
 
generation.
 
T. gondii–infected Mice Show Augmented Proinflammatory
Cytokine Production and Tissue Pathology in the Absence of 5-LO.
 
To determine whether the absence of 5-LO affects para-
site-induced proinflammatory cytokine responses, we stud-
ied the kinetics of serum IL-12, IFN-
 
 
 
, and TNF produc-
tion in 
 
T. gondii
 
–infected animals. Consistent with the
observation of lower parasite burdens, serum levels of IL-
12 and IFN-
 
  
 
were found to be significantly elevated in
infected 5-LO
 
 
 
/
 
  
 
mice compared with their wild-type
counterparts (Fig. 2, D and E). Particularly striking was the
 
uncontrolled increase in IL-12 production observed with
time in the knockout animals. Although serum TNF levels
also appeared to be elevated in the 5-LO
 
 
 
/
 
  
 
mice, the ob-
served increases were not statistically significant (Fig. 2 F).
The appearance of elevated proinflammatory cytokine
production in the presence of decreased parasite numbers
suggested that the increased mortality of 5-LO
 
 
 
/
 
  
 
mice re-
sults from cytokine-induced tissue damage. In support of
this hypothesis, brain sections from the knockout animals
25 d after infection showed markedly enhanced meningitis
when compared with equivalent sections from infected
wild-type control mice (unpublished data). In addition, the
5-LO–deficient brain tissue displayed increased encephalitis
with CD4
 
  
 
and CD8
 
  
 
cell infiltration (Fig. 3 A, 
 
d
 
 and 
 
e
 
,
and B). As expected from our recent findings demonstrat-
ing a suppressive influence of 5-LO on CCR5 expression
(10), staining for this chemokine receptor was also en-
hanced in the same sections from infected knockout mice
(Fig. 3 A, 
 
f
 
,
 
 
 
and C and D). In contrast to the brain, no evi-
dence of enhanced tissue damage was observed in the liver
and spleen of the same infected 5-LO
 
 
 
/
 
  
 
animals (unpub-
lished data).
When brain sections from the same infected wild-type
(Fig. 4 a) and 5-LO /  (Fig. 4 b) mice were stained for IL-
12p40 (red), a massive increase in the intensity of expres-
sion and frequency of positive cells was observed in the lat-
ter samples. Some, but not all of this staining was associated
with CD11c  cells (green), suggesting that in this model
5-LO regulates IL-12 expression in both DCs as well as
other cells in the tissue infiltrates.
In Vivo Administration of a Stable LXA4 Analogue Rescues
5-LO /  Mice from T. gondii–induced Mortality. Although
5-LO /  mice are clearly unable to produce LXA4 in re-
sponse to T. gondii infection, it was still possible that the
absence of a different 5-LO–dependent metabolic product
accounts for the increased IL-12 production and mortality
seen in the knockout animals. To attempt to confirm the
role of LXA4  in the 5-LO–dependent suppression ob-
served, we reconstituted T. gondii–infected 5-LO–deficient
animals by injecting them every other day with a stable
analogue of LXA4 (15-epi-16-phenoxy-parafluor-LXA4-
methyl ester). To additionally examine possible redundan-
cies in the activities of LXA4 and IL-10, a second group of
infected 5-LO /  mice was injected with IL-10 using the
same regimen. As expected, nonreconstituted 5-LO / 
animals succumbed  25–28 d after infection (Fig. 5 A).
However, treatment with 0.25 mg/kg LX analogue res-
cued these animals from death increasing their survival time
to  80 d (Fig. 5 A and unpublished data). In contrast, IL-
10–treated 5-LO /  mice succumbed much earlier, be-
tween 43 and 50 d after infection. Interestingly, when
brain cysts were enumerated on day 25, an increased fre-
quency (P   0.05) was observed in the IL-10–treated wild-
type and 5-LO /  animal groups when compared with
those assayed in untreated control groups (Fig. 5 B). In
contrast, LX analogue treatment caused a smaller but signif-
icant elevation in the cyst counts in the brains of 5-LO / 
mice but did not affect cyst numbers in wild-type animals.
Figure 1. LXA4 and IL-10 are induced with different kinetics during
T. gondii infection. Wild-type and 5-LO–deficient mice were infected in-
traperitoneally with 20 cysts of T. gondii (ME49 strain) and at the indi-
cated times the animals were bled and LXA4 and IL-10 levels were assessed
by ELISA in the serum. The values represent mean   SD of triplicate
samples of at least three animals per time point per group. The experi-
ment shown is representative of two performed.1256 Endogenous Lipoxin A4 Suppresses Parasite-induced Immunopathology
Nevertheless, LX treatment restored parasite burdens in the
5-LO /  tissues to the levels observed in the 5-LO–suffi-
cient controls (Fig. 5 B).
To additionally analyze the effects of LX and IL-10 re-
constitution, we evaluated serum levels of IL-12, IL-10,
and IFN-  20 d after infection, a time point at which IL-
12 production in wild-type animals has stabilized but
remains elevated with respect to uninfected mice. As
previously described (Fig. 2), nonreconstituted infected
5-LO /  mice displayed significantly higher levels of IL-
12 and IFN-  than these infected control animals. Impor-
tantly, LX treatment significantly lowered the concentra-
tions of both cytokines and in the case of IFN- , restored
its concentration to the level observed in wild-type con-
trols (Fig. 5, C and D). In contrast, LX analogue adminis-
tration had no detectable effect on IL-10 levels (Fig. 5 E),
arguing that the activity of the compound is not due to
the stimulation of IL-10 production. On the other hand,
IL-10 treatment of both wild-type and knockout animals
caused decreases in both IL-12 and IFN-  as well as an in-
crease in endogenous IL-10 (Fig. 5, C–E). Neither IL-10
or LX analogue treatment resulted in significant changes
in LXA4 levels in sera of either wild-type or 5-LO–defi-
cient animals (unpublished data). The above experiments
argue that the increased susceptibility of 5-LO /  mice to
T. gondii is the result of the loss of LX production and that
LX and IL-10 regulate cytokine production and host mor-
tality by different mechanisms.
Distinct Roles of IL-10 and LXA4 in the Regulation of In-
flammation and Macrophage Effector Function. To additionally
investigate the immunosuppressive functions of LXA4 with
respect to those of IL-10, we compared the efficacy of the
Figure 2. 5-LO    mice infected
with  T. gondii display profound
weight loss and accelerated mortality
despite the presence of lower para-
site burdens and elevated proin-
flammatory  cytokine production.
Wild-type (B6, 129J F2) and 5-LO–
deficient (B6, 129J Alox-5) animals
(males and females) were infected as
described in Fig. 1 and (A) body
weight and (B) survival rates were
monitored during the times indi-
cated (n   15 animals per group, per
experiment). (C) To evaluate para-
site load, the animals were killed and
cysts were counted in brain homog-
enates. For systemic cytokine pro-
duction, mice were bled at the indi-
cated time points and the levels of
(D) IL-12p40, (E) IFN- , and (F)
TNF were measured in serum by
ELISA. The values presented are the
mean   SD of at least three animals
per time point per group. The ex-
periments shown are representative
of at least two performed that gave
similar results. *, statistically signifi-
cant (P   0.05) differences between
the means of the values obtained
with 5-LO–deficient versus wild-
type control mice.1257 Aliberti et al.
two mediators in a variety of assays of microbicidal and
proinflammatory response. To measure their effects on
lymphokine-mediated intracellular control of parasite
growth, we preincubated elicited peritoneal macrophages
with LXA4 or IL-10 and then infected the cells with ta-
chyzoites of T. gondii in the presence of IFN- . After 48 h,
the macrophages were Giemsa stained and the number of
intracellular parasites was evaluated by microscopy. As
shown in Fig. 6 A, IL-10, but not LXA4 suppressed the mi-
crobiostatic effects of IFN-   on intracellular T. gondii
growth. Consistent with this observation, IL-10, but not
LXA4 inhibited nitric oxide production by the same cells
(Fig. 6 B). In contrast, both IL-10 and LXA4 pretreatment
suppressed TNF (Fig. 6 C), MIP-1 , and RANTES (un-
published data) production whereas IL-10 slightly en-
hanced and LXA4 markedly inhibited MIP-1   secretion
(Fig. 6 D) in these cultures. Thus, although LXA4 lacks the
suppressive effects on macrophage effector function dis-
Figure 3. Uncontrolled encepha-
litis and leukocyte infiltration in the
brains of 5-LO    mice chronically
infected with T. gondii. (A) Frozen
sections of brains of wild-type con-
trols (a, b, and c) and 5-LO /  (d, e,
and f) mice infected for 25 d with T.
gondii stained with anti-CD4 (a and
d), anti-CD8 (b and e), or anti-
CCR5 (c and f). Representative mi-
crographs ( 200) from at least three
animals per group are presented.
Arrows indicate reactive cells in the
section. The mean   SD of the total
counts of (B) CD3  CD4 , CD3 
CD8  cells or of the (C) CD11c 
CD11blo, CD11c  CD11bhi cells and
the intensity of the (D) latter cells
obtained from brain homogenates
(n     3) of the same experimental
groups is also shown. *, statistically
significant (P   0.05) differences be-
tween group means.1258 Endogenous Lipoxin A4 Suppresses Parasite-induced Immunopathology
played by IL-10, it shares with IL-10 the ability to inhibit
the proinflammatory cytokine and chemokine responses
generated by these cells upon lymphokine activation.
Discussion
IL-12 plays a fundamental role in the induction of both
innate and adaptive resistance to intracellular pathogens and
as a product of APC is a primary mediator of immune
function. Because of its potential toxicity when produced
in excess, IL-12 production is known to be carefully regu-
lated by a remarkably large number of different mecha-
nisms (16). The major mediators previously implicated in
the control of pathogen-induced IL-12 synthesis are the
down-regulatory cytokines IL-10 and TGF- . The results
presented here reveal a new in vivo pathway for the regula-
tion of IL-12–dependent antimicrobial immune responses
involving the eicosanoid LXA4.
LXA4 was originally described as a selective regulator of
leukotriene function (17) biosynthesized by leukocytes,
endothelial cells, and platelets by means of transcellular
pathway(s) (18). In later studies, LXA4 was shown to have
potent inhibitory effects on several inflammatory mecha-
nisms, including NK cell cytotoxicity (19), leukocyte re-
sponses to cytokines (e.g., TNF; reference 20), or to micro-
bial stimulation (21), neutrophil and eosinophil migration
(22, 23), as well as cell surface expression of P selectin and
LFA-1 (24, 25).
The possibility that LXA4 centrally regulates immune re-
sponses was suggested by our recent findings indicating that
the eicosanoid suppresses STAg-induced production of IL-
12 by DCs both in vitro and in vivo (10). Although the
Figure 4. Enhanced IL-12p40 production by CD11c 
and CD11c  cells in the brains of 5-LO /  mice chronically
infected with T. gondii. (a) The same frozen sections of brain
from wild-type and (b) 5-LO    mice analyzed in Fig. 3
were double stained with anti-CD11c (green) or anti–IL-12p40
(red) and counterstained with DAPI (blue). Representative
micrographs ( 200) from at least three animals per group
are presented.1259 Aliberti et al.
molecular mechanism for this inhibition was not elucidated
we proposed that it involves the down-regulation of
CCR5 expression as a consequence of interaction of LXA4
with the formyl-peptide receptor-like receptor (FPRL) 1, a
phenomenon previously described when FPRL-1 on hu-
man monocytes interacts with a peptide from HIV Gp120
(26). Although it is not yet clear whether FPRL-1 is the re-
ceptor responsible for these biological effects of LXA4, a re-
cent study in which the transfection of HeLa cells with
FPRL-1 led to LXA4 responsiveness as assessed by the inhi-
bition of nuclear factor  B activation (27) supports the ex-
istence of this pathway. Regardless of the precise mecha-
nism involved, it is clear from both the latter study and our
own previous observations that exogenous LXA4 can have
profound global effects on the immune response to micro-
bial stimulation inhibiting DC migration and function as
well as the induction of proinflammatory gene expression
(10, 27).
Although our previous experiments also suggested that
STAg itself induces LXA4-mediated inhibition of DC
function in vivo, they did not address the physiological
relevance of this response during natural infection. This
study establishes that LXA4 is induced by T. gondii in vivo
and this response plays a major host protective role in
preventing parasite-induced inflammation and mortality.
Upon infection with the protozoan, 5-LO /  mice suc-
cumbed during the early chronic phase but displayed a sig-
nificantly reduced parasite load. Instead, mortality ap-
Figure 5. In vivo administration
of a stable analogue of LXA4 rescues
5-LO    animals from mortality in-
duced by T. gondii infection. Wild-
type controls or 5-LO /   mice
were infected with T. gondii as de-
scribed above and treated every
other day from days 10 to 20 with
vehicle (0.2 ml/animal/time), LXA4
analogue (1  g/animal/time), or
IL-10 (0.1  g/animal/time). (A)
Survival rates, (B) cysts counts, (C)
serum IL-12, and (D) serum IFN- 
levels were assessed as previously
described. Values presented are the
mean   SD of triplicate samples of
five animals per group. *, statisti-
cally significant (P   0.05) differ-
ences between group means.1260 Endogenous Lipoxin A4 Suppresses Parasite-induced Immunopathology
peared to be associated with profound weight loss,
elevated proinflammatory cytokine production, and en-
hanced inflammation as reflected in an increased but dif-
fuse infiltration of CD4 , CD8 , and CCR5  cells in
brain tissue. The latter observation may reflect a loss of
regulation of chemokine and chemokine receptor expres-
sion as a consequence of impaired LX production. Inter-
estingly, in direct contrast to our previously published
findings on the effects of IL-10 deficiency in T. gondii in-
fection (3, 9), the infected 5-LO /  mice showed no obvi-
ous increase in hepatic inflammation/necrosis when com-
pared with infected control animals.
In situ staining of brain sections from infected 5-LO / 
animals revealed a striking increase in IL-12 expression rel-
ative to sections from wild-type mice, suggesting that the
enhanced production of the cytokine might be a major fac-
tor in the increased pathology and mortality observed. Al-
though this observation supports the results of our previous
study, indicating increased production of IL-12 in the
spleens of STAg-injected 5-LO /  mice (10), the findings
differ in that both CD11c  and CD11c  cells contribute to
the response seen in infected brain in the experiments re-
ported here. The latter discrepancy may simply reflect the
dominance of DCs in the innate response to STAg in the
spleen versus the more complex population of IL-12–pro-
ducing cells generated during chronic infection.
Because 5-LO controls the production of a number of
different eicosanoids (e.g., LTB4), it was necessary to con-
firm that the effects of 5-LO deficiency were the direct re-
sult of the failure to produce LXA4. Importantly, the re-
constitution of 5-LO /  mice with LX analogue early in
infection resulted in complete protection against parasite-
induced mortality and restored both IL-12 and IFN-  to
levels comparable to those in infected wild-type animals.
Although this observation does not rule out the possible
participation of other 5-LO dependent eicosanoids, it ar-
gues strongly that LXA4 is sufficient to mediate the protec-
tion against cytokine-associated mortality revealed by the
behavior of T. gondii–exposed 5-LO–deficient animals.
A major question raised by our findings concerns the rel-
ative roles of IL-10 and LXA4 in regulating IL-12–depen-
dent IFN-  production during T. gondii infection. The ob-
servations that IL-10–deficient mice succumb 10–14 d after
infection whereas 5-LO /  mice survive for an additional
10–15 d suggests that these two down-regulatory mediators
may have distinct functions but work in synergy to protect
the host against excess proinflammatory cytokine produc-
tion. Consistent with this hypothesis is our observation that
the reconstitution of 5-LO /  mice with IL-10 at a time
when endogenous IL-10 levels have waned protects the
animals for a short period of only 15–20 d, in contrast to
the long-lasting protection induced by LXA4 reconstitu-
tion. These findings suggest that although IL-10 is suffi-
cient to down-regulate IL-12 and other proinflammatory
cytokines during initial acute infection, LXA4 is necessary
to sustain long-term stabilization of these responses during
chronic infection. Because it is now clear that the contin-
ued IL-12 production is required for the maintenance of
host resistance to the parasite (14), it is possible that LXA4
may provide a mechanism for fine-tuning this response not
afforded by IL-10 alone. In this regard, our observation
that LXA4 lacks the suppressive activities on macrophage
effector functions displayed by IL-10 (Fig. 5) supports the
concept that its key role in T. gondii infection may be to
regulate IL-12–dependent IFN-  responses.
Figure 6. Redundant and nonredundant roles of IL-10 and LXA4 in
the regulation of proinflammatory function. Thioglycollate-elicited mac-
rophages were incubated with medium alone, 100 ng/ml IL-10, or 100
ng/ml LXA4. After 1 h, cells were infected with tachyzoites of the RH
strain of T. gondii (5:1 parasite/macrophage ratio) with or without the
addition of 100 ng/ml IFN- . (A) After an additional 48-h incubation,
cells were fixed, Giemsa stained, and the number of intracellular parasites
was determined by microscopic examination. In a parallel set of macro-
phage cultures, supernatants were harvested at 24 h and (B) NO2, (C)
TNF, and (D) MIP-1  production was determined as described in Mate-
rials and Methods. Bars represent mean   SD of triplicate measurements
performed on cells pooled from five animals. The results shown are repre-
sentative of two independent experiments performed. *, statistically sig-
nificant (P   0.05) differences between group means.1261 Aliberti et al.
Although the results of this study point to a major role
for endogenous LXA4 in the regulation of IL-12 respon-
siveness to T. gondii infection, it is important to note that
the IL-12 response to this parasite is unusual in its depen-
dence on CCR5 signaling. Thus, it is presently unclear
whether this LX may exert the same regulatory effects on
proinflammatory cytokine production induced by other
pathogens. Nevertheless, the observation that exogenous
LXA4 dramatically inhibits proinflammatory cytokine gene
expression in murine epithelial cells exposed to Salmonella
typhimurium (27) as well as our own observation that LXA4-
treated mice show highly defective DC migration in re-
sponse to LPS as well as STAg (10) argues that if induced
by microbial stimulation, LXA4 can have broad effects on
the host response to infection. Therefore, a key question is
whether other pathogens, in addition to T. gondii, trigger
endogenous LXA4 production. The identification of the
specific microbial products that stimulate LXA4 biosynthesis
and the signaling pathway(s) involved should yield infor-
mation important for our understanding of the immuno-
regulation of the response to pathogens as well as the de-
velopment of new strategies for manipulating the induction
of this potent antiinflammatory mediator.
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